Sarah Frances Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah Frances Bell has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
R.E. Collis
Department of Anaesthesia, Cardiff and Vale University Health Board, Cardiff, UK
5 shared publications- Lucy de Lloyd
Department of Anaesthetics, Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, United Kingdom
4 shared publications P.W. Collins
Cardiff Univ, Inst Infect & Immun, Sch Med, Cardiff, Wales
4 shared publications- Peter W. Collins
Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
4 shared publications Rachel E. Collis
Department of Anaesthetics, Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, United Kingdom
3 shared publicationsC. Bailey
Betsi Cadwaladr Univ Hlth Board, Glan Clwyd Hosp, Dept Anaesthet, Intens Care & Pain Med, Bodelwyddan, England
2 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1301-1310
Variation in antenatal anaemia guidelines across the NHS in the United Kingdom : A cross‐sectional study
Summary: Antenatal anaemia affects up to 30% of pregnant women in the United Kingdom and is a recognised clinical priority. National management guidance is published by the British Society of Haematology (BSH), but the extent to which local National Health Service (NHS) guidelines align with it is unknown. We conducted a cross‐sectional document analysis of antenatal anaemia guidelines from 49 NHS sites across the United Kingdom, obtained through two national research programmes. Two reviewers independently extracted data on screening, diagnosis, treatment and monitoring, using the 2020 BSH guideline as the national reference standard. The included guidelines represented approximately 33% of annual UK births. Screening and diagnostic haemoglobin thresholds were broadly consistent with BSH guidance, whereas substantial variation was concentrated in treatment and monitoring: oral iron indications, dosing and duration; haemoglobin thresholds and clinical criteria for intravenous iron; and the timing, biomarkers and response definitions used after treatment. Ferritin thresholds, reassessment intervals and response criteria were frequently absent or divergent. Variation was greatest in domains where the underlying evidence base is least resolved. These findings characterise the nature and extent of guideline‐level variation across NHS maternity care and identify priority areas for future research and national guideline development.
- 20 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1301-1310
Open AccessVariation in antenatal anaemia guidelines across the NHS in the United Kingdom : A cross‐sectional study
Summary: Antenatal anaemia affects up to 30% of pregnant women in the United Kingdom and is a recognised clinical priority. National management guidance is published by the British Society of Haematology (BSH), but the extent to which local National Health Service (NHS) guidelines align with it is unknown. We conducted a cross‐sectional document analysis of antenatal anaemia guidelines from 49 NHS sites across the United Kingdom, obtained through two national research programmes. Two reviewers independently extracted data on screening, diagnosis, treatment and monitoring, using the 2020 BSH guideline as the national reference standard. The included guidelines represented approximately 33% of annual UK births. Screening and diagnostic haemoglobin thresholds were broadly consistent with BSH guidance, whereas substantial variation was concentrated in treatment and monitoring: oral iron indications, dosing and duration; haemoglobin thresholds and clinical criteria for intravenous iron; and the timing, biomarkers and response definitions used after treatment. Ferritin thresholds, reassessment intervals and response criteria were frequently absent or divergent. Variation was greatest in domains where the underlying evidence base is least resolved. These findings characterise the nature and extent of guideline‐level variation across NHS maternity care and identify priority areas for future research and national guideline development.
- Open Access
- 25 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2173-2181
Rapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay
Postpartum hemorrhage (PPH) remains the leading cause of pregnancy-related mortality worldwide. Regardless of the initiating cause, continued bleeding may progress to a systemic coagulopathy. This coagulopathy may be complicated further by profound fibrinolytic activation that progresses to systemic hyperfibrinolysis, a condition that we have termed acute obstetric coagulopathy (AOC). Patients with placental abruption or amniotic fluid embolism are among those at highest risk for AOC. In response to the unmet need for a rapid method to detect fibrinolytic activation in this scenario, we developed a novel assay that we have termed the fibrinolytic activity screening test (FAST). This assay measures endogenously generated plasmin activity in plasma within 5 minutes. Its high sensitivity for the detection of in vivo fibrinolytic activation was confirmed by strong correlation with elevated plasmin-antiplasmin (PAP) complex levels. We analyzed archived plasma samples from 33 women with PPH and 20 pregnant women just before elective cesarean delivery. Of the 33 patients with PPH, 12 had PAP complex levels >25 000 ng/mL, thereby meeting criteria for the diagnosis of AOC. Plasmin activity measured by the FAST assay differentiated AOC from non-AOC PPH (P = .0007) and from pregnant non-PPH control groups (P< .0001) and was strongly correlated with both PAP complex and D-dimer levels. Among patients with PPH for whom viscoelastic whole blood testing (ROTEM) was performed, none of the 18 without AOC or 9 of those with AOC had evidence of ROTEM-defined hyperfibrinolysis. The FAST assay is a rapid tool to detect activation of fibrinolysis associated with AOC in women after delivery.
- 25 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2173-2181
Open AccessRapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay
Postpartum hemorrhage (PPH) remains the leading cause of pregnancy-related mortality worldwide. Regardless of the initiating cause, continued bleeding may progress to a systemic coagulopathy. This coagulopathy may be complicated further by profound fibrinolytic activation that progresses to systemic hyperfibrinolysis, a condition that we have termed acute obstetric coagulopathy (AOC). Patients with placental abruption or amniotic fluid embolism are among those at highest risk for AOC. In response to the unmet need for a rapid method to detect fibrinolytic activation in this scenario, we developed a novel assay that we have termed the fibrinolytic activity screening test (FAST). This assay measures endogenously generated plasmin activity in plasma within 5 minutes. Its high sensitivity for the detection of in vivo fibrinolytic activation was confirmed by strong correlation with elevated plasmin-antiplasmin (PAP) complex levels. We analyzed archived plasma samples from 33 women with PPH and 20 pregnant women just before elective cesarean delivery. Of the 33 patients with PPH, 12 had PAP complex levels >25 000 ng/mL, thereby meeting criteria for the diagnosis of AOC. Plasmin activity measured by the FAST assay differentiated AOC from non-AOC PPH (P = .0007) and from pregnant non-PPH control groups (P< .0001) and was strongly correlated with both PAP complex and D-dimer levels. Among patients with PPH for whom viscoelastic whole blood testing (ROTEM) was performed, none of the 18 without AOC or 9 of those with AOC had evidence of ROTEM-defined hyperfibrinolysis. The FAST assay is a rapid tool to detect activation of fibrinolysis associated with AOC in women after delivery.
- Open Access
- 30 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (11) , 2751-2762
Acute obstetric coagulopathy is associated with excess plasmin generation and proteolysis of fibrinogen and factor V
Hemostatic impairment may exacerbate postpartum hemorrhage (PPH). Previously, we described a distinct coagulopathy, associated with multiple causes of PPH including placental abruption and amniotic fluid embolus, termed acute obstetric coagulopathy (AOC). AOC is characterized by very high plasmin/antiplasmin complexes and rapid depletion of functional fibrinogen and factor V (FV). To determine mechanisms underlying AOC, we investigated the plasma from 12 women with AOC (defined by raised plasmin/antiplasmin) and 21 with severe PPH (blood loss >2000 mL or placental abruption) without AOC. Plasma from patients with AOC had a fourfold increased ability to generate plasmin compared with those with severe PPH without AOC (P < .0002). AOC was associated with fibrinogen cleavage in the circulation, demonstrated by fragment D and other breakdown products (P < .0001). D-dimer was increased 36-fold in AOC compared with severe PPH without AOC, thrombin/antithrombin complexes were not raised. FV was reduced on western blot in AOC but not severe PPH without AOC (P < .001) suggesting FV cleavage. Confocal microscopy revealed similar clot structure between AOC and non-AOC samples, but both groups differed from nonbleeding pregnant controls. These data suggest that in AOC an excess of plasmin cleaves fibrinogen and FV in the circulation causing a specific, pathognomonic depletion of coagulation factors. Fibrin(ogen) breakdown products have cofactor function for tissue plasminogen activator, and these data are consistent with these breakdown products, enhancing plasmin generation and potentially driving aberrant plasmin generation in AOC. These results have implications for the clinical management of coagulopathy during PPH.
- 30 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (11) , 2751-2762
Open AccessAcute obstetric coagulopathy is associated with excess plasmin generation and proteolysis of fibrinogen and factor V
Hemostatic impairment may exacerbate postpartum hemorrhage (PPH). Previously, we described a distinct coagulopathy, associated with multiple causes of PPH including placental abruption and amniotic fluid embolus, termed acute obstetric coagulopathy (AOC). AOC is characterized by very high plasmin/antiplasmin complexes and rapid depletion of functional fibrinogen and factor V (FV). To determine mechanisms underlying AOC, we investigated the plasma from 12 women with AOC (defined by raised plasmin/antiplasmin) and 21 with severe PPH (blood loss >2000 mL or placental abruption) without AOC. Plasma from patients with AOC had a fourfold increased ability to generate plasmin compared with those with severe PPH without AOC (P < .0002). AOC was associated with fibrinogen cleavage in the circulation, demonstrated by fragment D and other breakdown products (P < .0001). D-dimer was increased 36-fold in AOC compared with severe PPH without AOC, thrombin/antithrombin complexes were not raised. FV was reduced on western blot in AOC but not severe PPH without AOC (P < .001) suggesting FV cleavage. Confocal microscopy revealed similar clot structure between AOC and non-AOC samples, but both groups differed from nonbleeding pregnant controls. These data suggest that in AOC an excess of plasmin cleaves fibrinogen and FV in the circulation causing a specific, pathognomonic depletion of coagulation factors. Fibrin(ogen) breakdown products have cofactor function for tissue plasminogen activator, and these data are consistent with these breakdown products, enhancing plasmin generation and potentially driving aberrant plasmin generation in AOC. These results have implications for the clinical management of coagulopathy during PPH.
- Open Access
- 10 May 2025
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 63, 104683
Maternal physiological parameters and routine laboratory tests to screen for maternal sepsis: an observational cohort study
- 10 May 2025
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 63, 104683
Open AccessMaternal physiological parameters and routine laboratory tests to screen for maternal sepsis: an observational cohort study
- Open Access
- 25 October 2024
- Published by Wiley in Anaesthesia
- Vol. 80 (1) , 104-106
Relationship between the dual platelet‐inhibited ROTEM ® Sigma FIBTEM assay and Clauss fibrinogen during postpartum haemorrhage
- 25 October 2024
- Published by Wiley in Anaesthesia
- Vol. 80 (1) , 104-106
Open AccessRelationship between the dual platelet‐inhibited ROTEM ® Sigma FIBTEM assay and Clauss fibrinogen during postpartum haemorrhage
- Open Access
- 1 January 2024
- Published by Wiley in Anaesthesia Reports
- Vol. 12 (1) , e12293
ObsTIVA‐UK: a service evaluation of obstetric total intravenous anaesthesia in the United Kingdom
Summary: We conducted a prospective observational service evaluation across the United Kingdom on the use of total intravenous anaesthesia (TIVA) for obstetric surgery between November 2022 and June 2023. The primary aim was to describe the incidence of TIVA for obstetric surgery within participating units, with secondary aims to describe maternal and neonatal postoperative recovery indicators. Of 184 maternity units in the United Kingdom, 30 (16%) contributed data to the service evaluation. There were 104 patients who underwent caesarean delivery under TIVA and 19 patients had TIVA for other reasons. Infusions of propofol and remifentanil were used in 100% and 84% of cases, respectively. Fifty‐nine out of 103 live neonates (57%) required some form of respiratory support. Of the neonates with recorded data, 73% and 17% had Apgar scores < 7 at 1 and 5 min respectively. No neonates were recorded to have Apgar scores < 7 at 10 min. Further prospective research is required to investigate the impact of obstetric TIVA on maternal and neonatal outcomes and inform best practice recommendations.
- 1 January 2024
- Published by Wiley in Anaesthesia Reports
- Vol. 12 (1) , e12293
Open AccessObsTIVA‐UK: a service evaluation of obstetric total intravenous anaesthesia in the United Kingdom
Summary: We conducted a prospective observational service evaluation across the United Kingdom on the use of total intravenous anaesthesia (TIVA) for obstetric surgery between November 2022 and June 2023. The primary aim was to describe the incidence of TIVA for obstetric surgery within participating units, with secondary aims to describe maternal and neonatal postoperative recovery indicators. Of 184 maternity units in the United Kingdom, 30 (16%) contributed data to the service evaluation. There were 104 patients who underwent caesarean delivery under TIVA and 19 patients had TIVA for other reasons. Infusions of propofol and remifentanil were used in 100% and 84% of cases, respectively. Fifty‐nine out of 103 live neonates (57%) required some form of respiratory support. Of the neonates with recorded data, 73% and 17% had Apgar scores < 7 at 1 and 5 min respectively. No neonates were recorded to have Apgar scores < 7 at 10 min. Further prospective research is required to investigate the impact of obstetric TIVA on maternal and neonatal outcomes and inform best practice recommendations.
- 3 April 2023
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 21 (8) , 2064-2077
Managing the coagulopathy of postpartum hemorrhage: an evolving role for viscoelastic hemostatic assays
- 3 April 2023
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 21 (8) , 2064-2077
Managing the coagulopathy of postpartum hemorrhage: an evolving role for viscoelastic hemostatic assays